Literature DB >> 22716509

Murine double minute 2 promoter SNP309 polymorphism and prostate cancer risk: a meta-analysis.

Guoyuan Liu1, Deke Jiang, Suqin Shen, Long Yu.   

Abstract

OBJECTIVE: The murine double minute 2 gene encodes a negative regulator of the tumor protein p53. A single nucleotide polymorphism in murine double minute 2 promoter, SNP309 T>G, has been reported to alter murine double minute 2 protein expression and to accelerate tumor formation in humans. We carried out a meta-analysis to explore the association between this polymorphism and prostate cancer risk.
METHODS: All eligible studies were searched in PubMed. Crude odds ratios, with 95% confidence intervals, were assessed for the association using fixed- and random-effects models.
RESULTS: Overall, five case-control studies (872 cases, 1005 controls) were included in the meta-analysis. A significant association between murine double minute 2 SNP309 and prostate cancer risk was observed for homozygote genetic model GG versus TT (odds ratio 0.72, 95% confidence interval 0.55-0.95, P < 0.05, P = 0.130 for heterogeneity), and for dominant model TG + GG versus TT (odds ratio 0.79, 95% confidence interval 0.65-0.96, P < 0.05, P = 0.119 for heterogeneity). The stratified analysis based on ethnicity showed a significant effect of the polymorphism on prostate cancer risk in Caucasians for GG versus TT.
CONCLUSIONS: Findings of the present meta-analysis suggest that the murine double minute 2 309 G allele might be associated with a reduced risk of prostate cancer. The effect of murine double minute 2 309 G allele on tumorigenesis might be influenced by sex and hormonal status.
© 2012 The Japanese Urological Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22716509     DOI: 10.1111/j.1442-2042.2012.03067.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  8 in total

1.  MDM2 SNP309T>G polymorphism and hepatocellular carcinoma risk: a meta-analysis.

Authors:  Qi-Wen Chen; Hao Chen; Jian-Shan Cheng; Zhi-Qiang Meng
Journal:  Tumour Biol       Date:  2013-12-31

2.  Association of MDM2 promoter T309G polymorphism with oral cancer risk: A meta-analysis of 3,536 subjects.

Authors:  X I Yang; Yun Zhu; Dongxia Ye; Yang Liu; Hongying Sun; Min Ruan; Wei Liu
Journal:  Mol Clin Oncol       Date:  2016-04-20

3.  Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes.

Authors:  G J Ortiz; Y Li; S M Post; V Pant; S Xiong; C A Larsson; A K El-Naggar; D G Johnson; G Lozano
Journal:  Oncogene       Date:  2017-09-18       Impact factor: 9.867

4.  MDM2 SNP309 variation confers the susceptibility to hepatocellular cancer: a meta-analysis based on 4271 subjects.

Authors:  Jinli Lv; Bo Zhu; Liang Zhang; Qichao Xie; Wenlei Zhuo
Journal:  Int J Clin Exp Med       Date:  2015-04-15

5.  Association between MDM2 SNP309 T>G polymorphism and the risk of bladder cancer: new data in a Chinese population and an updated meta-analysis.

Authors:  Linguo Xie; Yan Sun; Tao Chen; Dawei Tian; Yujuan Li; Yu Zhang; Na Ding; Zhonghua Shen; Hao Xu; Xuewu Nian; Nan Sha; Ruifa Han; Hailong Hu; Changli Wu
Journal:  Onco Targets Ther       Date:  2015-12-07       Impact factor: 4.147

6.  Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate.

Authors:  Liv B Gansmo; Lars Vatten; Pål Romundstad; Kristian Hveem; Bríd M Ryan; Curtis C Harris; Stian Knappskog; Per E Lønning
Journal:  Oncotarget       Date:  2016-05-10

7.  MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk.

Authors:  Liv B Gansmo; Merete Bjørnslett; Mari Kyllesø Halle; Helga B Salvesen; Pål Romundstad; Kristian Hveem; Lars Vatten; Anne Dørum; Per E Lønning; Stian Knappskog
Journal:  BMC Cancer       Date:  2017-02-03       Impact factor: 4.430

8.  Rapid detection of SNP (c.309T>G) in the MDM2 gene by the Duplex SmartAmp method.

Authors:  Yasuaki Enokida; Kimihiro Shimizu; Jun Atsumi; Alexander Lezhava; Yuki Tanaka; Yasumasa Kimura; Takahiro Soma; Takeshi Hanami; Yuki Kawai; Kengo Usui; Yasuko Okano; Seiichi Kakegawa; Hiroomi Ogawa; Yohei Miyamae; Yohei Miyagi; Haruhiko Nakayama; Toshihisa Ishikawa; Yoshihide Hayashizaki; Izumi Takeyoshi
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.